Acme United Q2 2026 Earnings Beat Estimates on MyMedic Acquisition and Margin Expansion

• Acme United Corporation (ACU) delivered second-quarter 2026 earnings that significantly exceeded analyst expectations, with diluted EPS reaching $1.22 against a consensus estimate of $0.81.
• The company reported revenue of $62.72 million, surpassing forecasts of $58.08 million by nearly 8% and marking a 16% year-over-year sales increase.
• Stock price surged approximately 11.9% to 17.5% following the release, moving near its 52-week high of $51.88 as investors reacted to the strong financial beat.

The earnings beat was primarily fueled by the acquisition of MyMedic, which contributed significantly to the top-line growth. Excluding the impact of the acquisition, the company demonstrated 8% organic growth, indicating underlying operational strength. Gross margins also expanded to 42.6% from 41.0% in the prior year period, signaling improved operational efficiency or a favorable product mix.

Operational efficiency improved markedly across the board. EBITDA reached $8.801 million, representing a 136.78% increase from the prior year period. The EBITDA margin expanded to 14.03%, up from previous levels, indicating strong control over operating costs relative to sales. EBIT stood at $6.83 million, further underscoring the company's ability to convert top-line growth into bottom-line profitability.

CEO Johnsen provided commentary on the outlook, expecting continued margin recovery as the company transitions inventory. Specifically, lower-cost stock is replacing higher-tariff inventory throughout the remainder of the year, which should alleviate some cost pressures from ongoing trade tensions. The company is also integrating MyMedic, with a strategic focus on expanding distribution beyond its direct-to-consumer model into mass retail channels. Strong seasonal demand is anticipated to drive profitability in Q4.

Despite the positive results, several risks remain that warrant investor attention. Selling, General, and Administrative (SG&A) expenses are elevated at 32% of sales, potentially compressing net income. Additional headwinds include potential tariff and freight cost fluctuations, currency volatility, and uneven performance across geographic regions. Canada currently lags behind other markets, presenting a specific regional risk that management is monitoring closely.

How Did the MyMedic Acquisition Impact Growth?

The acquisition of MyMedic played a pivotal role in Acme United's Q2 2026 performance. Sales growth was robust, rising 16% year-over-year, with the acquisition being a significant contributor to this increase. On an organic basis, excluding acquisition contributions, sales grew by 8%, demonstrating that the core business remains healthy and capable of independent expansion.

Strategic focus remains on the MyMedic integration. While currently strong in direct-to-consumer channels, management is prioritizing expansion into mass retail to diversify revenue streams. This move is expected to broaden the customer base and reduce dependency on a single distribution model. The integration is ongoing, and management anticipates that the full benefits of this strategic expansion will materialize in subsequent quarters.

What Are the Key Financial Risks and Headwinds?

Investors should note several key risks associated with Acme United's current operational profile. SG&A expenses remain elevated at 32% of sales, which is a concern given the competitive landscape. The company faces potential headwinds from tariffs, freight costs, and currency fluctuations, which could impact future margins.

Geographic performance is uneven, with Canada currently lagging behind other regions. This disparity suggests that regional strategies may need adjustment to ensure balanced growth. Additionally, the company's beta is low at 0.49, indicating lower volatility than the broader market, but this also means the stock may not fully capture upside in a bull market. Dividend yield is 1.13%, slightly below the industry average of 1.47%, and dividend growth rate is 6.67%, underperforming the industry's 8.62% growth.

The company maintains a robust balance sheet with a current ratio of 3.23 compared to an industry average of 2.33, signaling strong short-term liquidity. However, profitability metrics such as Basic EPS and Diluted EPS trail the industry, indicating operational efficiency challenges relative to competitors. Asset turnover is notably higher than the industry average, suggesting efficient use of assets to generate sales, but this must be balanced against the lower profitability metrics.

Looking ahead, the company anticipates strong Q4 profitability driven by seasonal demand, particularly for its safety and medical products. The transition from higher-tariff inventory to lower-cost stock is expected to continue mitigating the impact of trade tensions. However, investors must remain vigilant regarding the elevated SG&A expenses and potential geographic performance disparities that could hinder future growth.

Acme United's Q2 2026 results highlight a company in transition, leveraging acquisitions to drive growth while navigating complex macroeconomic headwinds. The expansion in gross margins and operational efficiency provides a positive foundation, but the elevated SG&A and regional performance issues require careful monitoring. As the company integrates MyMedic and transitions inventory, the market will be watching closely to see if the projected margin recovery materializes in the coming quarters.